Phase 4 N=80 Randomized Treatment

Intravenous Versus Oral Iron in Late Pregnancy: Results of Treatment

Anemia · Pregnancy Complications

Bottom Line

View on ClinicalTrials.gov: NCT00746551 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Feb 2015

Primary outcome: Primary: Serum Ferritin Level — 136.1; 28.3 µg/dL

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Ferli-6® (Continental Pharm co., ltd.) (Drug); Venofer® (Vifor AG, St. Gallen, Switzerland) (Drug)
Age: Adult · 18+ yrs
Sex: Female
Sponsor: Mahidol University
Primary completion: Mar 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY Serum Ferritin Level	136.1; 28.3	—
SECONDARY Haemoglobin Level	10.6; 10.2	—

Summary

The purpose of this study is to compare the efficacy of body iron storage replenishment between low dose intravenous iron and oral iron in late pregnancy.

Eligibility Criteria

Inclusion Criteria

Age 18-45 years old
Singleton pregnancy at 32 weeks gestation
Having anemia in the third trimester according to World Health Organization, namely, with a hemoglobin level of 3 mg/L
Serum ferritin > 15 mcg/L

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00746551). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.